Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes.  As such, current antiplatelet therapy to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes.  However, managing PPG remains one of the most challenging aspects of diabetes care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
While a substantial body of research demonstrates the need to address the global epidemic of metabolic syndrome, and the constellation of associated cardiometabolic risk factors simultaneously, the majority of them are still treated as separate entities.The engaging and interactive session recordings from this Masterclass cover experts across specialties on the current state of affairs and advances in cardiometabolic disease including team based-care, telemedicine, cardio-renal risk reduction, obesity management, and much more.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases NAFLD and NASH, which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Metabolic syndrome and associated comorbidities, such as cardiovascular disease, obesity and type 2 diabetes, are becoming more common in women of reproductive age and beyond. In addition to traditional cardiometabolic risk factors, additional risk factors, including pregnancy-related outcomes, gestational diabetes mellitus, polycystic ovary syndrome, and hormonal replacement therapy, confer important implications on women's cardiometabolic health across the lifespan.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with heart failure (HF). Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with HF, ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The potential impacts of influenza coupled with those of COVID-19 have been termed as a potential “twindemic” coming for the US healthcare system. Although this early concern did not materialize, clinicians should pay attention to the diagnosis and management of influenza in the COVID-19 era and beyond, particularly in adults with multiple chronic comorbidities, including cardiovascular disease, obesity, diabetes, asthma and COPD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
During this Masterclass, expert faculty will discuss the links between sleep disorders and cardiometabolic health, as well as practical approaches for screening, referral, or treatment.

Pages